MONTREAL, QUEBEC--(Marketwire - June 26, 2008) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced it has received authorization from the Therapeutic Products Directorate of Health Canada to initiate a Phase II clinical trial evaluating TLN-232 as a treatment for metastatic melanoma in patients that have failed at least one prior therapy. The TLN-232 trial is the second Phase II study to be initiated this year from Thallion’s oncology pipeline.
